A4i is a software company developing a digital therapeutic for schizophrenia and psychosis. The software consists of a clinically-prescribed mobile app and clinical portal that allow clinicians to monitor patients’ condition, and enables patients to manage their own condition. The patient app features a patent-protected, clinically-tested engagement feed, and audio hallucination recognition tool that gives patients back their agency by letting them determine the veracity of auditory hallucinations.